Effects of Gold Fiducial Marker Implantation on Tumor Control and Toxicity in External Beam Radiotherapy of Prostate Cancer

Overview

Journal Radiol Oncol

Publisher Sciendo

Specialties Oncology
Radiology

Date 2023 Jan 18

PMID 36653352

Authors

Matthias Moll

Magdalena Weiss

Vladimir Stanisav

Alexandru Zaharie

Gregor Goldner

Affiliations

Soon will be listed here.

Abstract

Background: Evidence regarding the effects of fiducials in image-guided radiotherapy (IGRT) for tumor control and acute and late toxicity is sparse.

Patients And Methods: Patients with primary low- and intermediate-risk prostate cancer, 40 with and 21 without gold fiducial markers (GFM), and treated between 2010 and 2015 were retrospectively included. The decision for or against GFM implantation took anaesthetic evaluation and patient choice into account. IGRT was performed using electronic portal imaging devices. The prescribed dose was 78 Gy, with 2 Gy per fraction. Biochemical no evidence of disease (bNED) failure was defined using the Phoenix criteria. Acute and late gastrointestinal (GI) and genitourinary toxicity (GU) were assessed using the Radiation Therapy Oncology Group criteria.

Results: Most patients did not receive GFM due to contraindications for anaesthesia or personal choice (60% and 25%). Regarding tumor control, no significant differences were found regarding bNED and overall and disease-specific survival ( = 0.61, = 0.56, and > 0.9999, respectively). No significant differences in acute and late GI (p = 0.16 and 0.64) and GU toxicity ( = 0.58 and 0.80) were observed.

Conclusions: We were unable to detect significant benefits in bNED or in early or late GI and GU side effects after GFM implantation.

Citing Articles

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation.

Moll M, Goldner G Strahlenther Onkol. 2023; 200(3):188-194.

PMID: 37341774 PMC: 10876811. DOI: 10.1007/s00066-023-02104-7.

References

Wortel R, Incrocci L, Pos F, van der Heide U, Lebesque J, Aluwini S . Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. Int J Radiat Oncol Biol Phys. 2016; 95(2):680-9. DOI: 10.1016/j.ijrobp.2016.01.031. View

Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

Napieralska A, Majewski W, Kulik R, Glowacki G, Miszczyk L . A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients. Radiat Oncol. 2018; 13(1):235. PMC: 6258434. DOI: 10.1186/s13014-018-1171-2. View

Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley W, Sokol G . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-74. DOI: 10.1016/j.ijrobp.2006.04.029. View

Singh J, Greer P, White M, Parker J, Patterson J, Tang C . Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2012; 85(4):1018-23. DOI: 10.1016/j.ijrobp.2012.07.2376. View

Hamdy F, Donovan J, Athene Lane J, Mason M, Metcalfe C, Holding P . 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016; 375(15):1415-1424. DOI: 10.1056/NEJMoa1606220. View

Roach 3rd M, DeSilvio M, Valicenti R, Grignon D, Asbell S, Lawton C . Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006; 66(3):647-53. DOI: 10.1016/j.ijrobp.2006.05.074. View

Sveistrup J, Munck Af Rosenschold P, Deasy J, Oh J, Pommer T, Petersen P . Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014; 9:44. PMC: 3922544. DOI: 10.1186/1748-717X-9-44. View

Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020; 79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. View

10.

Pasalic D, Kuban D, Allen P, Tang C, Mesko S, Grant S . Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019; 104(4):790-797. PMC: 6579684. DOI: 10.1016/j.ijrobp.2019.02.045. View

11.

Kupelian P, Potters L, Khuntia D, Ciezki J, Reddy C, Reuther A . Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 58(1):25-33. DOI: 10.1016/s0360-3016(03)00784-3. View

12.

De Cicco L, Bracelli S . Fiducial markers implantation for prostate image-guided radiotherapy: a report on the transperineal approach. Radiol Med. 2018; 124(2):132-135. DOI: 10.1007/s11547-018-0949-5. View

13.

Zapatero A, Roch M, Buchser D, Castro P, Fernandez-Banda L, Pozo G . Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Clin Transl Oncol. 2017; 19(9):1161-1167. DOI: 10.1007/s12094-017-1655-9. View

14.

Gill S, Thomas J, Fox C, Kron T, Rolfo A, Leahy M . Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol. 2011; 6:145. PMC: 3217047. DOI: 10.1186/1748-717X-6-145. View

15.

Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S . The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS One. 2016; 11(5):e0154499. PMC: 4865138. DOI: 10.1371/journal.pone.0154499. View

16.

Wachter S, Gerstner N, Dorner D, Goldner G, Colotto A, Wambersie A . The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 52(1):91-100. DOI: 10.1016/s0360-3016(01)01821-1. View

17.

Peeters S, Heemsbergen W, Koper P, van Putten W, Slot A, Dielwart M . Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24(13):1990-6. DOI: 10.1200/JCO.2005.05.2530. View

18.

Zelefsky M, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X . Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(1):125-9. DOI: 10.1016/j.ijrobp.2011.11.047. View

19.

Dang A, Kupelian P, Cao M, Agazaryan N, Kishan A . Image-guided radiotherapy for prostate cancer. Transl Androl Urol. 2018; 7(3):308-320. PMC: 6043755. DOI: 10.21037/tau.2017.12.37. View

20.

Valeriani M, Bracci S, Osti M, Falco T, Agolli L, De Sanctis V . Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy. Radiat Oncol. 2013; 8:137. PMC: 3691824. DOI: 10.1186/1748-717X-8-137. View